ImmunityBio jumps as ANKTIVA global rollout optimism builds ahead of new AUA data
IBRX•ImmunityBio shares are rising after fresh investor focus on ANKTIVA’s expanding global commercialization and new data disclosures planned for an upcoming urology conference. The move comes despite lingering U.S. regulatory overhang tied to FDA promotional correspondence disclosed in April 2026.
1) What’s driving the stock today
ImmunityBio (IBRX) is moving higher as traders rotate back into the name on renewed optimism around ANKTIVA’s international expansion and near-term medical-meeting visibility. Comments highlighting “unstoppable” global expansion and plans to present new comparative ANKTIVA data at the upcoming American Urological Association (AUA) Annual Meeting have helped lift sentiment into today’s session. (stocktwits.com)
